Roche touts drugs pipeline, rules out Merger and Acquisition just to boost sales Medical Dialogues Bureau7 Sept 2019 9:15 AM ISTRoche has twice upgraded 2019 sales forecasts, the latest time to mid- to high-single-digit percentage rate growth, as medicines including Ocrevus for...
Biocon, Mylan gets Canadian nod for biosimilar of cancer drug Herceptin Farhat Nasim23 May 2019 11:59 AM ISTOgivri is the first trastuzumab biosimilar approved in Canada and the second biosimilar from Biocon and Mylan's joint portfolio approved in the...
USFDA approves Mylan, Biocon's Fulphila, the first biosimilar to Neulasta Ruby Khatun Khatun6 Jun 2018 10:30 AM ISTHERTFORDSHIRE/PITTSBURGH and BENGALURU: Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's...
Roche lymphoma drug drives high remission rate, longer survival: study Ruby Khatun Khatun12 Dec 2017 10:00 AM ISTAn experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced,...
Roche drug cocktail doubles chance of holding lung cancer at bay Ruby Khatun Khatun9 Dec 2017 9:45 AM ISTZURICH: Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease...
Roche sues Pfizer to bar biosimilar of cancer drug Herceptin Ruby Khatun Khatun22 Nov 2017 10:00 AM ISTRoche Holding AG, facing pressure in Europe as cheaper biosimilars of its three biggest cancer medicines chew away at its revenue, sued to block...
Roche stock up 12 billion dollars on cancer, hemophilia trials; rivals hit Ruby Khatun Khatun22 Nov 2017 10:00 AM ISTZURICH: Roche shares were lifted on Monday by two trial wins for its new cancer and hemophilia drugs, potential blockbusters that the Swiss drugmaker...
Roche MS drug Ocrevus wins European panel backing Ruby Khatun Khatun13 Nov 2017 10:02 AM ISTZURICH: Swiss drugmaker Roche on Friday won a key European panel's recommendation for its multiple sclerosis drug Ocrevus, which is on track for...
Roche Perjeta regimen gets FDA priority review in breast cancer Ruby Khatun Khatun4 Oct 2017 9:20 AM ISTZURICH: The U.S. Food and Drug Administration (FDA) has granted a priority review for Roche's Perjeta in combination with Herceptin and chemotherapy...
Roche eye drug fails late-stage trial in blow to pipeline Ruby Khatun Khatun11 Sept 2017 9:32 AM ISTZURICH: A drug Roche had hoped would prevent loss of vision and become a big seller failed a late-stage trial, leading some analysts to say on Friday...
Europe ready to embrace first copies of biotech cancer drugs supriya kashyap kashyap17 Feb 2017 12:25 PM ISTLondon : Treatment with two important cancer drugs is about to get much cheaper in Europe with a cut-price copy of Roche's blood cancer drug Rituxan...
